Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 218.38M | 191.20M | 196.00M | 170.99M | 150.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 218.38M | 191.20M | 196.00M | 170.99M | 150.04M |
| Cost of Revenue | 13.56M | 14.73M | 12.33M | 11.91M | 13.45M |
| Gross Profit | 204.81M | 176.48M | 183.67M | 159.08M | 136.59M |
| SG&A Expenses | 208.14M | 185.00M | 169.30M | 150.24M | 130.28M |
| Depreciation & Amortization | 1.59M | 1.57M | 1.61M | 1.61M | 1.59M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 269.52M | 253.97M | 232.02M | 203.92M | 194.86M |
| Operating Income | -51.14M | -62.77M | -36.03M | -32.92M | -44.82M |
| Income Before Tax | -51.19M | -64.54M | -28.13M | -47.23M | -48.93M |
| Income Tax Expenses | 128.00K | -- | 430.00K | -- | -960.00K |
| Earnings from Continuing Operations | -51.31M | -64.54M | -28.56M | -47.23M | -47.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.31M | -64.54M | -28.56M | -47.23M | -47.97M |
| EBIT | -51.14M | -62.77M | -36.03M | -32.92M | -44.82M |
| EBITDA | -48.26M | -60.40M | -33.75M | -30.51M | -42.57M |
| EPS Basic | -0.99 | -1.26 | -0.56 | -0.94 | -0.97 |
| Normalized Basic EPS | -0.64 | -0.78 | -0.46 | -0.43 | -0.59 |
| EPS Diluted | -0.99 | -1.26 | -0.56 | -0.94 | -0.97 |
| Normalized Diluted EPS | -0.64 | -0.78 | -0.46 | -0.43 | -0.59 |
| Average Basic Shares Outstanding | 51.80M | 51.20M | 50.63M | 50.02M | 49.44M |
| Average Diluted Shares Outstanding | 51.80M | 51.20M | 50.63M | 50.02M | 49.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |